SILO PHARMA, INC. Business Combination, Consideration Transferred
SILO PHARMA, INC. (SILO) reported Business Combination, Consideration Transferred of $152.24 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-20.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation
us-gaap:BusinessCombinationConsiderationTransferred1 · last filed 2020-03-20
- SILO PHARMA, INC. business combination, consideration transferred for fiscal 2019 was $152.24K.
| Period end | Business Combination, Consideration Transferred 1 month | Business Combination, Consideration Transferred 1 month as first filed | Business Combination, Consideration Transferred 12 month |
|---|---|---|---|
| 2019-12-31 | $152.24K 10-K · filed 2020-03-20 | ||
| 2018-09-29 | $152.24K 10-K · filed 2019-04-04 | $300.00K 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |